CorMedix Stock Rating Reiterated by H.C. Wainwright After Quarter

H.C. Wainwright has reiterated its stock rating for CorMedix following the company's strong quarterly performance. Key details about the financial performance were not provided, but the reaffirmation of the rating indicates confidence in CorMedix’s business outlook. This decision reflects the analysts' positive assessment of the company's potential in the market. For investors, maintaining a favorable rating could signify stability and potential growth for CorMedix (CRMD) moving forward.